Tesamorelin 10mg — Research Protocol

Tesamorelin is a synthetic 44-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH)^[1]. It stimulates endogenous growth hormone release and raises IGF-1 levels, leading to enhanced lipolysis and metabolic benefits^[2]. Tesamorelin is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy and is studied for metabolic disorders and aging research^[3][4].

Storage Instructions

Proper storage preserves peptide quality and efficacy.

• Lyophilized: Store at 2–8 °C (35.6–46.4 °F); newer formulations (Egrifta SV) stable at 20–25 °C (68–77 °F) before reconstitution^[1].
• Reconstituted (with bacteriostatic water): Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days^[1].
• Reconstituted (with sterile water): Use immediately; discard any unused portion^[1].
• Do not freeze reconstituted solution; avoid repeated freeze-thaw cycles.

How It Works

esamorelin mimics natural human GHRH by binding to pituitary GHRH receptors, triggering pulsatile growth hormone secretion and consequent IGF-1 elevation^[2]. This cascade promotes lipolysis (fat breakdown), protein synthesis, and favorable metabolic shifts. In HIV-associated lipodystrophy, daily tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles over 6–12 months^[3][4]. Research also explores tesamorelin’s potential to reduce liver fat in NAFLD patients and enhance cognitive function in older adults by restoring age-related GH/IGF-1 declines^[4].

Potential Benefits & Side Effects

Observations from clinical trials and FDA-approved use.

Potential Benefits:

• Significant reduction in visceral adipose tissue (measurable after 3–6 months)^[3].
• Improved lipid profiles and potential liver fat reduction in NAFLD^[4].
• Enhanced cognitive function in older adults (research ongoing)^[4].
• Well-tolerated with maintained benefits during continuous use up to 52 weeks^[3].

Common Side Effects:

• Injection-site reactions: Mild redness, itching, pain, or bruising at injection area^[9].
• Musculoskeletal symptoms: Joint pain (arthralgia), muscle aches, peripheral edema (mild swelling)^[9].
• Carpal tunnel symptoms: Occasional tingling or numbness in extremities (dose-dependent, reversible).
• Metabolic monitoring: IGF-1 elevation requires monitoring; small increases in HbA1c observed in some patients^[9].

Lifestyle Factors

Complementary strategies for optimal outcomes.

• Combine with a balanced, protein-forward diet to support GH/IGF-1 anabolic effects.
• Integrate resistance training and aerobic activity to maximize fat loss and metabolic benefits.
• Prioritize 7–9 hours of quality sleep to optimize natural GH pulsatility.
• Manage stress through mindfulness or relaxation techniques to support adherence and recovery.

Reference

• Tesamorelin – LiverTox: Clinical and Research Information on Drug-Induced Liver InjuryNational Institutes of Health, NIDDK (2018)
• Tesamorelin (Subcutaneous route) – Drug InformationMayo Clinic / IBM Merative (2025)
• Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trialsJ. Clin. Endocrinol. Metab. (2010)
• Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: A randomized, placebo-controlled trialPLoS ONE (2017)
• Tesamorelin can improve cognitive function (Research Highlight)Nature Reviews Endocrinology (2012)
• Tesamorelin Injection – MedlinePlus Drug InformationMedlinePlus (U.S. National Library of Medicine) (2025)
• Tesamorelin: Uses, Dosage, Side Effects, WarningsDrugs.com (AHFS Monograph & Patient Info) (2025)
• Tesamorelin – LiverTox (Safety Profile)NIH NIDDK LiverTox Database (2018)
• Administration of Parenteral Medications – Nursing Skills (Open RN Textbook)Open RN, Chippewa Valley Technical College (2023)